DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Remdesivir |
DMBFZ6L
|
Moderate |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Remdesivir. |
1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]
|
[7] |
Tagraxofusp |
DM9HQ5U
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Tagraxofusp. |
Acute myeloid leukaemia [2A60]
|
[8] |
Gilteritinib |
DMTI0ZO
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Gilteritinib. |
Acute myeloid leukaemia [2A60]
|
[8] |
Inotersen |
DMJ93CT
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Inotersen. |
Amyloidosis [5D00]
|
[8] |
Ivabradine |
DM0L594
|
Moderate |
Decreased metabolism of BMS-201038 caused by Ivabradine mediated inhibition of CYP450 enzyme. |
Angina pectoris [BA40]
|
[9] |
Bedaquiline |
DM3906J
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Bedaquiline. |
Antimicrobial drug resistance [MG50-MG52]
|
[8] |
Troleandomycin |
DMUZNIG
|
Major |
Decreased metabolism of BMS-201038 caused by Troleandomycin mediated inhibition of CYP450 enzyme. |
Bacterial infection [1A00-1C4Z]
|
[7] |
Pexidartinib |
DMS2J0Z
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Pexidartinib. |
Bone/articular cartilage neoplasm [2F7B]
|
[10] |
Talazoparib |
DM1KS78
|
Moderate |
Decreased clearance of BMS-201038 due to the transporter inhibition by Talazoparib. |
Breast cancer [2C60-2C6Y]
|
[11] |
LY2835219 |
DM93VBZ
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and LY2835219. |
Breast cancer [2C60-2C6Y]
|
[8] |
Tucatinib |
DMBESUA
|
Major |
Decreased metabolism of BMS-201038 caused by Tucatinib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[7] |
Palbociclib |
DMD7L94
|
Moderate |
Decreased metabolism of BMS-201038 caused by Palbociclib mediated inhibition of CYP450 enzyme. |
Breast cancer [2C60-2C6Y]
|
[9] |
Fenofibric acid |
DMGO2MC
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Fenofibric acid. |
Cardiovascular disease [BA00-BE2Z]
|
[8] |
Macitentan |
DMP79A1
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Macitentan. |
Cardiovascular disease [BA00-BE2Z]
|
[8] |
Fidaxomicin |
DMFP6MV
|
Minor |
Decreased clearance of BMS-201038 due to the transporter inhibition by Fidaxomicin. |
Clostridium difficile enterocolitis [1A04]
|
[7] |
Regorafenib |
DMHSY1I
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Regorafenib. |
Colorectal cancer [2B91]
|
[8] |
Intedanib |
DMSTA36
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Intedanib. |
Colorectal cancer [2B91]
|
[8] |
Levonorgestrel |
DM1DP7T
|
Moderate |
Decreased metabolism of BMS-201038 caused by Levonorgestrel mediated inhibition of CYP450 enzyme. |
Contraceptive management [QA21]
|
[8] |
Osilodrostat |
DMIJC9X
|
Moderate |
Decreased metabolism of BMS-201038 caused by Osilodrostat mediated inhibition of CYP450 enzyme. |
Cushing syndrome [5A70]
|
[9] |
MK-8228 |
DMOB58Q
|
Major |
Decreased metabolism of BMS-201038 caused by MK-8228 mediated inhibition of CYP450 enzyme. |
Cytomegaloviral disease [1D82]
|
[7] |
Polatuzumab vedotin |
DMF6Y0L
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Polatuzumab vedotin. |
Diffuse large B-cell lymphoma [2A81]
|
[8] |
Oestradiol valerate and dienogest |
DMZK0FQ
|
Moderate |
Decreased metabolism of BMS-201038 caused by Oestradiol valerate and dienogest mediated inhibition of CYP450 enzyme. |
Endometriosis [GA10]
|
[12] |
Stiripentol |
DMMSDOY
|
Moderate |
Decreased metabolism of BMS-201038 caused by Stiripentol mediated inhibition of CYP450 enzyme. |
Epilepsy/seizure [8A61-8A6Z]
|
[9] |
Cannabidiol |
DM0659E
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Cannabidiol. |
Epileptic encephalopathy [8A62]
|
[8] |
Tazemetostat |
DMWP1BH
|
Moderate |
Decreased metabolism of BMS-201038 caused by Tazemetostat mediated inhibition of CYP450 enzyme. |
Follicular lymphoma [2A80]
|
[13] |
Mirabegron |
DMS1GYT
|
Minor |
Decreased metabolism of BMS-201038 caused by Mirabegron mediated inhibition of CYP450 enzyme. |
Functional bladder disorder [GC50]
|
[14] |
Ripretinib |
DM958QB
|
Moderate |
Decreased metabolism of BMS-201038 caused by Ripretinib mediated inhibition of CYP450 enzyme. |
Gastrointestinal stromal tumour [2B5B]
|
[7] |
Avapritinib |
DMK2GZX
|
Moderate |
Decreased metabolism of BMS-201038 caused by Avapritinib mediated inhibition of CYP450 enzyme. |
Gastrointestinal stromal tumour [2B5B]
|
[9] |
Boceprevir |
DMBSHMF
|
Major |
Decreased metabolism of BMS-201038 caused by Boceprevir mediated inhibition of CYP450 enzyme. |
Hepatitis virus infection [1E50-1E51]
|
[7] |
177Lu-DOTATATE |
DMT8GVU
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and 177Lu-DOTATATE. |
Hepatitis virus infection [1E50-1E51]
|
[8] |
Brentuximab vedotin |
DMWLC57
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Brentuximab vedotin. |
Hodgkin lymphoma [2B30]
|
[8] |
MK-1439 |
DM215WE
|
Minor |
Decreased metabolism of BMS-201038 caused by MK-1439 mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[15] |
Cobicistat |
DM6L4H2
|
Major |
Decreased metabolism of BMS-201038 caused by Cobicistat mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[7] |
Dolutegravir |
DMCZGRE
|
Minor |
Decreased metabolism of BMS-201038 caused by Dolutegravir mediated inhibition of CYP450 enzyme. |
Human immunodeficiency virus disease [1C60-1C62]
|
[16] |
Rilpivirine |
DMJ0QOW
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Rilpivirine. |
Human immunodeficiency virus disease [1C60-1C62]
|
[8] |
Aliskiren |
DM1BV7W
|
Moderate |
Decreased metabolism of BMS-201038 caused by Aliskiren mediated inhibition of CYP450 enzyme. |
Hypertension [BA00-BA04]
|
[6] |
Levamlodipine |
DM92S6N
|
Moderate |
Decreased metabolism of BMS-201038 caused by Levamlodipine mediated inhibition of CYP450 enzyme. |
Hypertension [BA00-BA04]
|
[8] |
Givosiran |
DM5PFIJ
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Givosiran. |
Inborn porphyrin/heme metabolism error [5C58]
|
[8] |
Berotralstat |
DMWA2DZ
|
Major |
Decreased metabolism of BMS-201038 caused by Berotralstat mediated inhibition of CYP450 enzyme. |
Innate/adaptive immunodeficiency [4A00]
|
[7] |
Suvorexant |
DM0E6S3
|
Moderate |
Decreased metabolism of BMS-201038 caused by Suvorexant mediated inhibition of CYP450 enzyme. |
Insomnia [7A00-7A0Z]
|
[7] |
Naloxegol |
DML0B41
|
Minor |
Decreased clearance of BMS-201038 due to the transporter inhibition by Naloxegol. |
Large intestine motility disorder [DB32]
|
[17] |
Pemigatinib |
DM819JF
|
Moderate |
Decreased metabolism of BMS-201038 caused by Pemigatinib mediated inhibition of CYP450 enzyme. |
Liver cancer [2C12]
|
[9] |
Crizotinib |
DM4F29C
|
Major |
Decreased metabolism of BMS-201038 caused by Crizotinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[7] |
Brigatinib |
DM7W94S
|
Moderate |
Decreased metabolism of BMS-201038 caused by Brigatinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[7] |
Ceritinib |
DMB920Z
|
Major |
Decreased metabolism of BMS-201038 caused by Ceritinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[7] |
Lurbinectedin |
DMEFRTZ
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Lurbinectedin. |
Lung cancer [2C25]
|
[8] |
PF-06463922 |
DMKM7EW
|
Moderate |
Decreased metabolism of BMS-201038 caused by PF-06463922 mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[18] |
Alectinib |
DMP1I6Y
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Alectinib. |
Lung cancer [2C25]
|
[8] |
Osimertinib |
DMRJLAT
|
Moderate |
Decreased metabolism of BMS-201038 caused by Osimertinib mediated inhibition of CYP450 enzyme. |
Lung cancer [2C25]
|
[19] |
BIBW 2992 |
DMTKD7Q
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and BIBW 2992. |
Lung cancer [2C25]
|
[8] |
Pralsetinib |
DMWU0I2
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Pralsetinib. |
Lung cancer [2C25]
|
[8] |
Capmatinib |
DMYCXKL
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Capmatinib. |
Lung cancer [2C25]
|
[8] |
Selpercatinib |
DMZR15V
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Selpercatinib. |
Lung cancer [2C25]
|
[8] |
Calaspargase pegol |
DMQZBXI
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Calaspargase pegol. |
Malignant haematopoietic neoplasm [2B33]
|
[8] |
Idelalisib |
DM602WT
|
Major |
Decreased metabolism of BMS-201038 caused by Idelalisib mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[7] |
GDC-0199 |
DMH0QKA
|
Moderate |
Decreased metabolism of BMS-201038 caused by GDC-0199 mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[7] |
IPI-145 |
DMWA24P
|
Major |
Decreased metabolism of BMS-201038 caused by IPI-145 mediated inhibition of CYP450 enzyme. |
Mature B-cell leukaemia [2A82]
|
[7] |
Acalabrutinib |
DM7GCVW
|
Moderate |
Decreased metabolism of BMS-201038 caused by Acalabrutinib mediated inhibition of CYP450 enzyme. |
Mature B-cell lymphoma [2A85]
|
[20] |
Blinatumomab |
DMGECIJ
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Blinatumomab. |
Mature B-cell lymphoma [2A85]
|
[8] |
Ibrutinib |
DMHZCPO
|
Moderate |
Decreased metabolism of BMS-201038 caused by Ibrutinib mediated inhibition of CYP450 enzyme. |
Mature B-cell lymphoma [2A85]
|
[21] |
Ponatinib |
DMYGJQO
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Ponatinib. |
Mature B-cell lymphoma [2A85]
|
[8] |
Arry-162 |
DM1P6FR
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Arry-162. |
Melanoma [2C30]
|
[8] |
Vemurafenib |
DM62UG5
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Vemurafenib. |
Melanoma [2C30]
|
[8] |
Selumetinib |
DMC7W6R
|
Moderate |
Decreased metabolism of BMS-201038 caused by Selumetinib mediated inhibition of CYP450 enzyme. |
Melanoma [2C30]
|
[22] |
Dabrafenib |
DMX6OE3
|
Moderate |
Increased metabolism of BMS-201038 caused by Dabrafenib mediated induction of CYP450 enzyme. |
Melanoma [2C30]
|
[9] |
Ubrogepant |
DM749I3
|
Moderate |
Decreased metabolism of BMS-201038 caused by Ubrogepant mediated inhibition of CYP450 enzyme. |
Migraine [8A80]
|
[23] |
Carfilzomib |
DM48K0X
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Carfilzomib. |
Multiple myeloma [2A83]
|
[8] |
Tecfidera |
DM2OVDT
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Tecfidera. |
Multiple sclerosis [8A40]
|
[8] |
Siponimod |
DM2R86O
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Siponimod. |
Multiple sclerosis [8A40]
|
[8] |
Fingolimod |
DM5JVAN
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Fingolimod. |
Multiple sclerosis [8A40]
|
[8] |
Fedratinib |
DM4ZBK6
|
Major |
Decreased metabolism of BMS-201038 caused by Fedratinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[7] |
Ruxolitinib |
DM7Q98D
|
Minor |
Decreased metabolism of BMS-201038 caused by Ruxolitinib mediated inhibition of CYP450 enzyme. |
Myeloproliferative neoplasm [2A20]
|
[9] |
Netupitant |
DMEKAYI
|
Major |
Decreased metabolism of BMS-201038 caused by Netupitant mediated inhibition of CYP450 enzyme. |
Nausea/vomiting [MD90]
|
[7] |
Entrectinib |
DMMPTLH
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Entrectinib. |
Non-small cell lung cancer [2C25]
|
[8] |
S-297995 |
DM26IH8
|
Moderate |
Decreased clearance of BMS-201038 due to the transporter inhibition by S-297995. |
Opioid use disorder [6C43]
|
[9] |
Olaparib |
DM8QB1D
|
Moderate |
Decreased metabolism of BMS-201038 caused by Olaparib mediated inhibition of CYP450 enzyme. |
Ovarian cancer [2C73]
|
[24] |
Rucaparib |
DM9PVX8
|
Moderate |
Decreased metabolism of BMS-201038 caused by Rucaparib mediated inhibition of CYP450 enzyme. |
Ovarian cancer [2C73]
|
[8] |
Abametapir |
DM2RX0I
|
Moderate |
Decreased metabolism of BMS-201038 caused by Abametapir mediated inhibition of CYP450 enzyme. |
Pediculosis [1G00]
|
[25] |
Lefamulin |
DME6G97
|
Moderate |
Decreased metabolism of BMS-201038 caused by Lefamulin mediated inhibition of CYP450 enzyme. |
Pneumonia [CA40]
|
[7] |
Relugolix |
DMK7IWL
|
Major |
Decreased clearance of BMS-201038 due to the transporter inhibition by Relugolix. |
Prostate cancer [2C82]
|
[26] |
Riociguat |
DMXBLMP
|
Moderate |
Decreased metabolism of BMS-201038 caused by Riociguat mediated inhibition of CYP450 enzyme. |
Pulmonary hypertension [BB01]
|
[7] |
Sarilumab |
DMOGNXY
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Sarilumab. |
Rheumatoid arthritis [FA20]
|
[8] |
Voxelotor |
DMCS6M5
|
Moderate |
Decreased metabolism of BMS-201038 caused by Voxelotor mediated inhibition of CYP450 enzyme. |
Sickle-cell disorder [3A51]
|
[8] |
LDE225 |
DMM9F25
|
Moderate |
Decreased metabolism of BMS-201038 caused by LDE225 mediated inhibition of CYP450 enzyme. |
Skin cancer [2C30-2C37]
|
[27] |
Larotrectinib |
DM26CQR
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Larotrectinib. |
Solid tumour/cancer [2A00-2F9Z]
|
[8] |
LEE011 |
DMMX75K
|
Major |
Decreased metabolism of BMS-201038 caused by LEE011 mediated inhibition of CYP450 enzyme. |
Solid tumour/cancer [2A00-2F9Z]
|
[7] |
Fostamatinib |
DM6AUHV
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Fostamatinib. |
Thrombocytopenia [3B64]
|
[8] |
Lusutrombopag |
DMH6IKO
|
Moderate |
Decreased clearance of BMS-201038 due to the transporter inhibition by Lusutrombopag. |
Thrombocytopenia [3B64]
|
[28] |
Lenvatinib |
DMB1IU4
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Lenvatinib. |
Thyroid cancer [2D10]
|
[8] |
Linagliptin |
DMWFJTR
|
Moderate |
Decreased clearance of BMS-201038 due to the transporter inhibition by Linagliptin. |
Type 2 diabetes mellitus [5A11]
|
[8] |
Elagolix |
DMB2C0E
|
Major |
Increased risk of hepatotoxicity by the combination of BMS-201038 and Elagolix. |
Uterine fibroid [2E86]
|
[8] |
Betrixaban |
DM2C4RF
|
Moderate |
Decreased clearance of BMS-201038 due to the transporter inhibition by Betrixaban. |
Venous thromboembolism [BD72]
|
[29] |
----------- |
|
|
|
|
|